within Pharmacolibrary.Drugs.ATC.J;

model J05AB12
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00295,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0088,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.013,
    k12             = 81.6,
    k21             = 81.6
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J05AB12</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Cidofovir is an acyclic nucleoside phosphonate antiviral medication, primarily used for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. It is approved for intravenous use and is generally reserved for cases where other treatments have failed or are not tolerated, due to its potential nephrotoxicity and limited oral bioavailability.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in HIV-infected patients with cytomegalovirus retinitis after a single intravenous dose.</p><h4>References</h4><ol><li><p>Lea, AP, &amp; Bryson, HM (1996). Cidofovir. <i>Drugs</i> 52(2) 225–231. DOI:<a href=&quot;https://doi.org/10.2165/00003495-199652020-00006&quot;>10.2165/00003495-199652020-00006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8841740/&quot;>https://pubmed.ncbi.nlm.nih.gov/8841740</a></p></li><li><p>Caruso Brown, AE, et al., &amp; Levin, MJ (2015). Pharmacokinetics and safety of intravenous cidofovir for life-threatening viral infections in pediatric hematopoietic stem cell transplant recipients. <i>Antimicrobial agents and chemotherapy</i> 59(7) 3718–3725. DOI:<a href=&quot;https://doi.org/10.1128/AAC.04348-14&quot;>10.1128/AAC.04348-14</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25733509/&quot;>https://pubmed.ncbi.nlm.nih.gov/25733509</a></p></li><li><p>Cundy, KC (1999). Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. <i>Clinical pharmacokinetics</i> 36(2) 127–143. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199936020-00004&quot;>10.2165/00003088-199936020-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10092959/&quot;>https://pubmed.ncbi.nlm.nih.gov/10092959</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J05AB12;
